Evidence map›Paper›PMID 42321978›Full record

ArticleProtein science : a publication of the Protein Society2026

Achieving protease substrate-specific inhibition by mAb dual functional selections.

Ki Baek Lee, Sangcheon Lee, Bharati Reddi, Sushma Krishnan, Zening Wang, Xin Ge

Abstract read
In one paragraph

Article in Protein science : a publication of the Protein Society, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

6 authors.

Ki Baek LeeTexas Therapeutics Institute, Institute of Molecular Medicine, University of Texas Health Science Center at Houston, Houston, Texas, USA.
Sangcheon LeeDepartment of Chemical and Environmental Engineering, University of California, Riverside, California, USA.ORCID 0009-0000-8455-9917
Bharati ReddiTexas Therapeutics Institute, Institute of Molecular Medicine, University of Texas Health Science Center at Houston, Houston, Texas, USA.
Sushma KrishnanTexas Therapeutics Institute, Institute of Molecular Medicine, University of Texas Health Science Center at Houston, Houston, Texas, USA.
Zening WangTexas Therapeutics Institute, Institute of Molecular Medicine, University of Texas Health Science Center at Houston, Houston, Texas, USA.ORCID 0000-0002-6975-1596
Xin GeTexas Therapeutics Institute, Institute of Molecular Medicine, University of Texas Health Science Center at Houston, Houston, Texas, USA.ORCID 0000-0001-7491-7805

Funding

Therapeutic Monoclonal Antibodies Inhibiting Proteases of Biomedical ImportanceR35GM141089 · NIGMS · UNIVERSITY OF TEXAS HLTH SCI CTR HOUSTON · PI GE, XIN · 2021 to 2025
$2.0M
Cancer Prevention and Research Institute of Texas RP21004NIGMS NIH HHS R35 GM141089NIGMS NIH HHS R35GM141089
6 · The paper itself

Abstract

Proteases are promiscuous enzymes acting on multiple substrates. Inhibiting pathogenic proteolysis while sparing physiological ones is essential for the development of effective and safe inhibitors. By engineering β-lactamase and levansucrase as selection and counterselection markers in E. coli periplasm, this study established functional positive and negative selections for the facile discovery of protease inhibitory mAbs rendering substrate specificity. Isolated anti-matrix metalloproteinase (MMP)-14 inhibitory mAbs exhibited nanomolar binding affinities and inhibitory potencies, exclusive selectivity, high proteolysis stability, and substrate-specific (SS) inhibition, that is, blocking MMP-14 mediated proteolysis of pro-tumorigenic syndecan-1 (Sdc-1) while allowing cleavage of anti-inflammatory macrophage chemoattractant protein 3 (MCP-3). Mechanistic studies suggested that the isolated Fabs were active-site competitive inhibitors and their substrate specificity was achieved by recognizing the protease's prime subsites shared with Sdc-1 but distinct to that of MCP-3. Given the pharmaceutical significance of SS inhibition, we envision the dual functional selection can be widely applicable to important protease targets.

Indexed as

Antibodies, MonoclonalProtease InhibitorsEscherichia coliHumansProteolysisSubstrate SpecificityAntibodies, MonoclonalProtease InhibitorslevansucrasemAbnegative selectionprotease inhibitorsubstrate‐specific inhibition

Identifiers

PMID42321978
PMCPMC13282273

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.